Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trialBernard Nordlinger, Thomas Gruenberger, Halfdan Sørbye et al.|The Lancet|2008Cited by 1.9k
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trialGunnar Folprecht, Claus‐Henning Köhne, Thomas Gruenberger et al.|The Lancet Oncology|2009Cited by 960
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah‐Eddin Al‐Batran, Andrea Tannapfel, Ralf‐Dieter Hofheinz et al.|The Lancet Oncology|2016Cited by 738
Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954Christoph Schuhmacher, Peter M. Schlag, Cornelie Haag et al.|Journal of Clinical Oncology|2010Cited by 714
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12Emmanouil Fokas, Michael Allgäuer, Bülent Polat et al.|Journal of Clinical Oncology|2019Cited by 536